Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia - Cancer Cell International
Source : https://cancerci.biomedcentral.com/articles/10.1186/s12935-023-03000-x
Background Acute myeloid leukaemia (AML) remains difficult to treat despite the development of novel formulations and targeted therapies. Activating mutations in the FLT3 gene are common among patients and make...
Conclusions: This study suggests that a multi-targeted intervention involving a CDK4/6 inhibitor with a FLT3 inhibitor or a pan-PI3K inhibitor might be a valuable therapeutic strategy for AML to overcome drug resistance. Moreover, many patients cannot tolerate high doses of the drugs that were studied (quizartinib, palbociclib and PI3K...
Conclusion: CD10 can be used as an independent prognostic stromal marker and this will help to envisage new therapeutic strategies.
Safety and Feasibility of CDK4/6 Inhibitors Treatment Combined with Radiotherapy in Patients with HR-positive/HER2-negative Breast Cancer A Systematic Review and Meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37536378/
The findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.
Conclusion: The findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37511548/
The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has revolutionized the treatment landscape for hormone receptor-positive breast cancer. These agents have demonstrated significant clinical benefits in terms...
Conclusions/Relevance: This review paper aims to outline the reported mechanisms underlying CDK4/6 inhibitor resistance, drawing insights from both clinical data and translational research in order to help direct the future of treatment for hormone receptor-positive metastatic breast cancer.
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer - Genome Medicine
Source : https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-023-01201-7
Background Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2− MBC); however, resistance...
Conclusions: We identified novel molecular features associated with poor prognosis and molecular mechanisms that could be targeted to overcome resistance to CKD4/6 plus ET.